Bastion Asset Management Inc. Has $14.36 Million Position in AngioDynamics, Inc. $ANGO

Bastion Asset Management Inc. decreased its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 11.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,118,180 shares of the medical instruments supplier’s stock after selling 145,823 shares during the quarter. AngioDynamics makes up approximately 7.9% of Bastion Asset Management Inc.’s portfolio, making the stock its largest position. Bastion Asset Management Inc.’s holdings in AngioDynamics were worth $14,357,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in ANGO. Goldman Sachs Group Inc. grew its position in AngioDynamics by 9.6% during the first quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock valued at $2,434,000 after buying an additional 22,658 shares during the period. Jane Street Group LLC grew its position in AngioDynamics by 267.1% during the first quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier’s stock valued at $439,000 after buying an additional 34,054 shares during the period. Legal & General Group Plc grew its position in AngioDynamics by 279.5% during the second quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier’s stock valued at $123,000 after buying an additional 9,098 shares during the period. Rhumbline Advisers grew its position in AngioDynamics by 4.3% during the second quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock valued at $608,000 after buying an additional 2,510 shares during the period. Finally, American Century Companies Inc. grew its position in AngioDynamics by 15.8% during the second quarter. American Century Companies Inc. now owns 96,808 shares of the medical instruments supplier’s stock valued at $960,000 after buying an additional 13,217 shares during the period. Institutional investors own 89.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ANGO shares. Canaccord Genuity Group reduced their price target on shares of AngioDynamics from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Monday, April 6th. Zacks Research downgraded shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a report on Monday, March 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a report on Monday, April 20th. Finally, Freedom Capital raised shares of AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $18.67.

AngioDynamics Stock Up 3.3%

NASDAQ ANGO opened at $11.43 on Wednesday. The company has a market cap of $472.45 million, a PE ratio of -15.25 and a beta of 0.37. AngioDynamics, Inc. has a 52 week low of $8.36 and a 52 week high of $13.99. The firm’s 50-day simple moving average is $10.77 and its two-hundred day simple moving average is $11.42.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Thursday, April 2nd. The medical instruments supplier reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.04. The business had revenue of $78.42 million for the quarter, compared to the consensus estimate of $76.77 million. AngioDynamics had a negative net margin of 10.01% and a negative return on equity of 4.66%. As a group, equities research analysts anticipate that AngioDynamics, Inc. will post -0.19 EPS for the current year.

AngioDynamics Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.